Abstract: This overview of the 4th edition of the World Health Organization (WHO) Classification of thymic tumors has two aims. First, to comprehensively list the established and new tumor entities and variants that are described in the new WHO Classification of thymic epithelial tumors, germ cell tumors, lymphomas, dendritic cell and myeloid neoplasms, and soft-tissue tumors of the thymus and mediastinum; second, to highlight major differences in the new WHO Classification that result from the progress that has been made since the 3rd edition in 2004 at immunohistochemical, genetic and conceptual levels. Refined diagnostic criteria for type A, AB, B1-B3 thymomas and thymic squamous cell carcinoma are given, and it is hoped that these criteria will improve the reproducibility of the classification and its clinical relevance. The clinical perspective of the classification has been strengthened by involving experts from radiology, thoracic surgery, and oncology; by incorporating state-of-theart positron emission tomography/computed tomography images; and by depicting prototypic cytological specimens. This makes the thymus section of the new WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart a valuable tool for pathologists, cytologists, and clinicians alike. The impact of the new WHO Classification on therapeutic decisions is exemplified in this overview for thymic epithelial tumors and mediastinal lymphomas, and future perspectives and challenges are discussed.
this interdisciplinary perspective on thymic tumors is further strengthened by involving clinical experts from radiology, thoracic surgery, and oncology as co-authors and by the incorporation of state-of-the-art computed tomography and positron emission tomography/computed tomography images ( Fig. 1 ) and cytology (Fig. 2) . The foundations for this interdisciplinary approach and the broad consensus on conceptual changes and histological criteria for improved thymoma subtyping were greatly aided by two international interdisciplinary conferences organized by the International Thymic Malignancy Interest Group (ITMIG) in New York City and Mannheim, Germany and convened experts from North America, Asia, and Europe. Another focus of the 4th edition was the revision and refinement of histological and immunohistochemical diagnostic criteria for a more robust and reproducible subtyping of thymomas and for the distinction between thymomas and thymic carcinomas. The necessary preparatory work for this refinement of histological criteria was achieved at the ITMIG consensus meetings in New York and Mannheim 5 and is reflected in the 4th edition not only in the "histopathology" but also "differential diagnosis" paragraphs. Furthermore, the epidemiological and prognostic data in the chapters on thymic epithelial tumors (TETs) were for the first time not only based on single-center experience or small meta-analysis, but on recent data derived from the worldwide, retrospective database of the ITMIG that has compiled more than 6000 cases of thymomas, thymic carcinomas, and thymic neuroendocrine neoplasms. [6] [7] [8] [9] In the chapters on germ cell tumors (GCTs), lymphoid, hematopoietic and soft-tissue neoplasms, there are no changes of concept or diagnostic criteria in the 4th compared with the 3rd edition. Minor revisions concern new immunohistochemical and genetic data and the adaptation of nomenclature and definitions to the WHO Classifications of Tumours of the Haematopoietic and Lymphoid Tissue, 10 Tumours of Soft Tissues and Bone 11 and Tumours of the Urinary System and Male Genital Organs (H. Moch, et al., forthcoming).
The following "overview" focuses on differences between the 3rd and 4th edition of the WHO Classification of tumors of the thymus rather than providing comprehensive description of the tumors.
NOVELTIES IN THE NEW WHO CLASSIFICATION OF MEDIASTINAL TUMORS Thymomas

Conceptual continuity
The nomenclature of the major thymoma subtypes based on letters and numbers (type A, AB, B1-B3) 2 is maintained in the 4th edition (Table 1) , as is the recommendation to use the modified Masaoka-Koga system for the staging of thymomas. 12 A new tumor, node, metastasis (TNM) staging system is currently being jointly developed by the International Association for the Study of Lung Cancer and ITMIG, but preliminary staging 
Conceptual changes
One new feature of the 4th edition is that some histological criteria for the characterization of thymomas using hematoxylin and eosin (HE)-stained specimens are now considered "obligatory/indispensable," and others as "optional" according to their importance for diagnosis (Table 2) . 5 It is hoped that these clarifications will reduce previous ambiguity and may help to overcome the unsatisfactory reproducibility of the WHO classification reported by some studies. [16] [17] [18] Another conceptual change concerns the reporting of more than 30% of thymomas that show more than one histological pattern (Moran et al. 19 find >50% on extensive sampling). 20 Instead of using the term "combined TETs," 1 the diagnosis should list all the histological thymoma types that are encountered, starting with the most prominent component; minor components should be reported subsequently and quantified in 10% increments. 5 This rule is not applicable to type AB thymoma (a distinct thymoma entity) and tumors with a carcinoma component of whatever size (see "Combined thymic carcinomas" below).
A third conceptual change is the introduction of immunohistochemical features as criteria for diagnosis of thymomas with ambiguous histology. Examples are the distinction of type A and AB thymomas by the paucity versus abundance of immature TdT+ T cells, or the different patterns of coarse versus delicate cytokeratin networks in type AB and B1 thymomas (see below). Routine immunohistochemical markers that are recommended in otherwise difficult-to-classify thymomas and thymic carcinomas are given in Table 3 . 3 A final conceptual change concerns the appreciation that all major thymoma subtypes can behave in a clinically aggressive fashion 19 and therefore should no longer be called benign tumors, irrespective of tumor stage. Accordingly, their ICD-O codes now have a /3 suffix, labeling them as malignant (Table 1) . Exceptions are micronodular and microscopic thymomas, for which fatal outcomes are not on record.
Key new discoveries
Improved genetic, [21] [22] [23] epigenetic, 24, 25 and transcriptomic 23, 26 analyses have augmented our knowledge about the distinct molecular basis of thymomas and thymic carcinomas. The latter show mutations of epigenetic regulatory genes, 21 methylation patterns, 25 and expression profiles of antiapoptotic genes 26 that clearly distinguish them from thymomas. On the other hand, the identification of a highly recurrent point mutation in the GTF2I oncogene in all major thymoma subtypes and thymic carcinomas 22 is a seminal finding that underlines the unique tumor biology of TETs and lends strong support to the WHO-based subtyping of thymic tumors. 27 Nevertheless, new predictive markers with therapeutic perspective are still awaited. 28, 29 Individual changes concerning thymoma subtypes Atypical type A thymoma: A new addition in the 4th edition is the delineation of an "atypical type A thymoma variant" from conventional type A thymomas ( Table 1 ). The new term reflects the experience that rare type A thymomas can show hypercellularity, increased mitotic activity, and The atypical type A thymoma variant (in bold) is the only new addition to the "historic" list of thymoma subtypes. necrosis (Fig. 3 ). Necrosis in particular appears to correlate with advanced stage, including metastasis. 5, [30] [31] [32] Rare type AB thymomas can show similar features. 30 The clinical significance of this variant needs further studies.
Type A versus AB thymoma:
The distinction between type A and AB thymoma has been notoriously difficult. [16] [17] [18] It is now stressed that both thymoma types share the occurrence of bland-looking spindle epithelial cells (that may optionally Beware of adenocarcinoma metastases to the mediastinum that can be CD5+ as well. Fig. 4A-C) . Any lymphocytedense areas (with crowded TdT+ cells that are "impossible to count" in "type B-like" areas) or more than 10% tumor areas with a moderate infiltrate of immature T cells should prompt classification as type AB thymoma. 5 The close relationship between type A and AB thymomas is strongly supported by largely overlapping genetic alterations. 22 However, it will be interesting to study whether this genetic overlap applies to lymphocyte-poor and lymphocyte-rich areas in type AB thymoma alike.
Type B thymomas and distinction from thymic carcinoma: Type B1 and B2 thymomas are, by definition, both lymphocyterich tumors. To improve their distinction from one another, which can be difficult, 17, 18 the thymus-like architecture and cytology of B1 thymomas are highlighted as obligatory criteria, including presence of medullary islands as a "must" and absence of epithelial cell clusters. By contrast, type B2 thymomas must show a higher than normal number of polygonal (nonspindle) neoplastic epithelial cells that usually occur in clusters (defined as three or more contiguous epithelial cells). Medullary islands optionally occur in type B2 thymomas, whereas Hassall's corpuscles occur as optional feature usually in type B1 and rarely in B2 thymomas (Table 2) . Cytokeratin (and p40/p63) expression patterns may be helpful to distinguish type B1 from type B2 (and AB) thymoma (Fig. 5) .
Type B3 thymoma is a lymphocyte-poor, epithelial-rich tumor but distinction from type B2 thymomas may be difficult. 5 Because of the lack of distinguishing markers, the differential diagnosis rests on the visual impression that type B2 thymomas look blue on HE staining (because of the presence of many admixed lymphocytes), whereas type B3 thymomas look pink (because of sheets of confluent tumor cells).
The distinction of type B3 thymoma from thymic squamous cell carcinoma (TSQCC) can be a challenge when rare tumors with a type B3 thymoma morphology show focal expression of "TSQCC-markers" (such as CD5 and CD117) and/or lack of "type B3 thymoma markers" (such as TdT+ T cells), or when tumors with a TSQCC morphology harbor (usually rare) TdT+ immature T cells. 5 In the 4th edition, it is now stated that tumors that look like type B3 thymoma on HE staining should be diagnosed as type B3 thymoma, and tumors with TSQCC morphology should be labeled as TSQCC, irrespective of immunohistochemistry.
Other thymomas: No major changes have been introduced. In metaplastic thymomas, exclusive staining of the polygonal but not the spindle cell component for p63 or p40 may be diagnostically helpful.
Thymic Carcinomas Including Combined Thymic Carcinomas
Conceptual continuity
With few exceptions [e.g., nuclear protein in testis (NUT) carcinomas, adenocarcinomas], the nomenclature and diagnostic criteria of almost all thymic carcinoma subtypes remain unchanged. The Masaoka-Koga staging system may still be used for thymic carcinomas till publication of the new UICC/AJCC-approved TNM system (supposedly in 2016).
Conceptual changes
The thymic adenocarcinomas are gathered in one chapter and labeled according to their HE histology, abandoning the distinction between papillary and nonpapillary adenocarcinomas.
Although the term "combined TETs" was abandoned in the 4th edition (see above), the term Combined thymic carcinomas was introduced for tumors that are either composed of different types of thymic carcinomas (extremely rare) or of a thymic carcinoma and any type of thymoma or carcinoid (rare). However, in analogy to the lung, heterogeneous TETs with a small-cell carcinoma (SCC) component or a large-cell neuroendocrine carcinoma (LCNEC) component are not counted among the combined thymic carcinomas but among the neuroendocrine carcinomas (see below). The reporting of a combined thymic carcinoma must start with the carcinoma component irrespective of its proportion, followed by the thymoma component. 5 In case of two or more carcinoma components, the dominant component is reported first.
Changes concerning individual thymic carcinoma subtypes
Thymic squamous cell carcinomas: FoxN1 and CD205 are novel markers 31 that complement CD5 and CD117 as markers that are expressed in most TSQCC but not in pulmonary squamous cell carcinomas. In 10% to 20% of mediastinal squamous cell carcinomas without expression of these markers, staging remains paramount to distinguish thymic from pulmonary primaries. Among the many new molecular findings in thymic carcinoma (reviewed by Rajan et al. 27 ) significant predictive markers remain to be identified.
Basaloid carcinoma of the thymus:
In the lung, carcinomas with basaloid features, including prominent palisading as hallmark, are termed "basaloid squamous cell carcinoma" and considered a high-grade variant of squamous cell carcinoma with distinct genetic features. 33 In the thymus, cancers with basaloid features show a more varied histology (including a wide range of proliferative activities, common macropapillary growth pattern, and association with cysts) and a broader spectrum of clinical aggressiveness. 34 Genetic data are sparse and not overlapping with those of pulmonary basaloid squamous cell carcinoma. 35 Therefore, the term "basaloid carcinoma of the thymus" is maintained in the 4th edition (Table 1) .
Mucoepidermoid carcinoma: Translocation of the MAML2 gene is characteristic of almost all low-grade mucoepidermoid carcinomas (MECs) and many high-grade MECs of salivary glands, 36 bronchi, and lung. 37 This translocation has recently been observed in thymic MECs as well, 38 allowing their distinction from adenosquamous carcinomas and adenocarcinomas.
FIGURE 5.
Immunohistochemical staining of keratin across the spectrum of type A to B3 thymomas. Of note, among the lymphocyte-rich thymomas a dense epithelial cell networks is typical of type AB and type B2 thymoma, whereas a delicate network is an obligatory feature of type B1 thymoma.
Sarcomatoid carcinoma:
The microscopic description of sarcomatoid carcinoma has been refined and now distinguishes (1) spindle cell carcinoma (malignant transformation of type A thymoma); (2) sarcomatoid transformation of preexisting thymic carcinoma; and (3) true carcinosarcoma with heterologous component(s).
Adenocarcinomas: Papillary adenocarcinomas of the thymus usually co-occur with type A and AB thymomas and are now defined as low-grade carcinomas, while high-grade adenocarcinomas with (usually focal) papillary growth are counted among the "adenocarcinomas, not otherwise specified."
Thymic carcinomas that were called "adenoid cystic carcinomas (ACC)" in the 3rd edition are now labeled as "thymic carcinomas with ACC-like features" in the 4th edition because they lack the immunohistochemical features of true ACC in other organs. 39 Enteric differentiation (as shown by immunohistochemistry) occurs in a subset of mucinous carcinomas and adenocarcinomas, NOS, and is currently of unknown clinical significance. Such cases require clinical staging to exclude metastasis from a colorectal primary.
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NUT carcinoma: These highly aggressive cancers that were first observed as midline thoracic tumors in children and young adults and harbored a unique t(15;19)-translocation with generation of a BRD4-NUT fusion oncogene were called "carcinoma with t(15;19) translocation" in the 3rd edition. These tumors are now known to occur at all ages, outside the thorax (and rarely outside the midline) in approximately 40% and to show variant NUT translocations in approximately 30% of cases. 41, 42 Therefore, these tumors are now labeled NUT carcinomas irrespective of anatomical location. Analysis for NUT overexpression by immunohistochemistry is now possible and highly sensitive and should be considered in any undifferentiated cancer, particularly if there is focal squamous differentiation.
Undifferentiated carcinoma: This tumor shows epithelial differentiation but is otherwise a diagnosis of exclusion. Poorly differentiated squamous cell carcinoma, lymphoepitheliomalike carcinoma, sarcomatoid carcinoma, NUT carcinoma, SCC and LCNEC, and adenocarcinoma of the thymus, GCT, extension from the lung and metastasis must be excluded. By definition, immunohistochemical markers (e.g., CK5/6, p63, CD5) of any of the aforementioned tumors are absent, but CD117 and PAX8 may be expressed.
Clinical relevance of refined thymoma and thymic carcinoma diagnosis
The first step when assessing a mediastinal mass is to establish a differential diagnosis between TETs, lymphomas, and other neoplasms, including metastasis. This relies on clinical presentation, including neurological examination, tumor marker profiles, and imaging features. 43 In thymic epithelial lesions, next steps are the differentiation of thymic malignancy from hyperplasia or noninvoluted thymus and the assessment of upfront resectability of the tumor, as complete resection is the most significant prognostic variable. In a postoperative setting, precise histopathological subtyping is of major importance for treatment decisions. In this setting, postoperative radiotherapy may be considered after complete resection of stage II thymomas with more aggressive histology, including B2 and B3 subtypes. Chemoradiotherapy is a major component of the therapeutic strategy of thymic carcinomas, as perioperative or exclusive treatment modality. 44 In advanced stage refractory disease, KIT mutations have exclusively been reported to occur in thymic carcinomas, but their potential role as biomarkers needs further studies; meanwhile, targeting angiogenesis using multikinase inhibitors is of higher relevance in carcinomas irrespective of their KIT mutational status. 45 By contrast, the histone deacetylase inhibitor, belinostat, 46 the insulin-like growth factor 1 receptor-targeting antibody, cixutumumab, 47 and somatostatin analogues 48 are more effective in thymomas. The importance of diagnosing NUT carcinoma results from the ineffectiveness of conventional chemotherapeutic regimens and availability of promising new targeted agents. 49 
Thymic Neuroendocrine Tumors
Conceptual continuity
These chapters cover neuroendocrine epithelial tumors (NETs), but not paraganglioma and neurogenic tumors. In the 4th edition, the nomenclature and criteria (Table 4) of thymic typical and atypical carcinoids, LCNEC, and SCC remain the same as in the 3rd edition. 1 The definition of "neuroendocrine differentiation" in the carcinoids and LCNECs, i.e., strong and diffuse expression of usually more than one of the four neuroendocrine markers (chromogranin A, synaptophysin, CD56, and neuron-specific enolase) in more than 50% of tumor cells, has been maintained. As before, SCC remains a histological diagnosis; expression of neuroendocrine markers is often present but not required.
Conceptual changes
The descriptive terms "well-differentiated neuroendocrine carcinoma" (referring to carcinoids) and "poorly differentiated neuroendocrine carcinoma" (referring to LCNEC and SCC) of the 3rd edition were abandoned, because LCNECs and even SCC may be highly differentiated in terms of neuroendocrine features. Following the strategy in the lung, the 
Key new findings
A major advance has been the elucidation of genetic alterations at the comparative genomic hybridization level by an international consortium. 50 The progressive increase and overlap of genetic gains and losses from typical carcinoids through atypical carcinoids to LCNECs and SCCs lend support to the WHO classification. Genetic alterations in thymic and pulmonary carcinoids are significantly different from each other, whereas the genetics of high-grade neuroendocrine tumors from thymus and lung are indistinguishable. 50 It is the currently favored concept that different molecular pathways lead to thymic carcinoids and thymic high-grade neuroendocrine carcinomas. 50 The recent description of shared genetic alterations in thymic carcinoids and associated synchronous or metachronous highgrade neuroendocrine carcinomas challenge this view 51 and suggest that transformation of carcinoids might be an alternative pathway leading to high-grade neuroendocrine carcinomas. 51, 52 There are currently no immunohistological markers that can unequivocally distinguish between thymic and pulmonary primaries, although a TTF1−/PAX8 (polyclonal)+ profile appears to be more common in thymic carcinoids. 53 Clinical and radiological correlation remains the mainstay for the distinction between thymic and pulmonary neuroendocrine tumors.
Individual changes in subtypes of thymic NETs
Except for new genetic data, there are no further changes in individual thymic NETs.
GCTs of the Mediastinum, Including GCTs with Somatic-Type Malignancy
Conceptual continuity
The nomenclature and histological criteria defining the main mediastinal GCT categories are maintained in the 4th edition of the WHO Classification with one minor exception: GCT with somatic-type malignancy that is a clonally related sarcoma, carcinoma, or both is now called "GCT with somatic-type solid malignancy" to stress the distinction from GCT with associated clonally related hematological malignancies. GCTs with the latter variant of somatic-type malignancy are unique to the mediastinum and called "GCTs with associated hematological malignancy" (Table 5 ).
Conceptual changes
There have been no conceptual changes.
Individual changes of GCT subtypes
The classic immunohistological markers (keratins, placental alkaline phosphatase, CD117; CD30; alpha-fetoprotein; β-subunit of human chorionic gonadotropin) are usually sufficient to recognize even complex GCTs. Several new markers, such as OCT4, glypican 3, and SOX2 (Table 5) , may help to more precisely delineate the individual components.
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Lymphomas of the Mediastinum
Conceptual continuity, no conceptual changes
The "new" classification of mediastinal lymphomas was streamlined according to the 4th edition of the WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues. 10 There have been no conceptual changes (Table 1) .
Individual changes of lymphoma subtypes
Primary mediastinal large B-cell lymphomas: The typical immunophenotype of primary mediastinal large B-cell lymphomas (PMBL) as reported in the 3rd edition 1 (CD20+ CD79a+ PAX5+ CD30+/− CD15− CD10− IRF4/MUM1+/− HLADR−) has been complemented, among others, by CD23 (positive in 70%) and p63 (positive in >90%), whereas p40 is absent. 57 As a caveat, p63 is also expressed in normal and neoplastic thymic epithelial cells, 58 although it is typically accompanied by p40 expression. 59 Despite a characteristic immunohistochemical profile, and a gene expression profile that extensively overlaps with that of Hodgkin lymphoma (HL) but not other B-cell lymphomas, 60 the diagnosis of PMBL in daily practice still requires clinical data (particularly absence of extensive extrathoracic lymph node infiltration) to exclude systemic diffuse large B-cell lymphoma with mediastinal involvement.
Among the novel genetic alterations reported since 2004, the following are of special interest from a biological and potentially immunotherapeutic perspective: translocations of the HLA class II transactivator CIITA at 16p13.13 associated with downregulation of human leukocyte antigen class II molecules and the almost specific amplification and/or translocation of the 9p24.1 region including the loci coding for the immune checkpoint molecules PD-L1 and programmed death-ligand-2 (PD-L2), 61, 62 which are overexpressed and helpful immunohistochemical markers in PMBL.
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MALT lymphoma: New genetic findings include a high frequency of trisomy 3, low incidence of trisomy 18, and no translocations involving MALT1 and IGH. 64, 65 T lymphoblastic leukemia/lymphoma: The new edition highlights a subset of TdT-negative cases. 66 The latter might be related to early thymic progenitor T-ALLs that coexpress early myeloid markers and stem cell markers (CD34 and CD117). These are considered high-risk subgroups. 67, 68 Among many novel genetic alterations detected, mutations of NOTCH1/FXBW are associated with a favorable outcome, 69 whereas loss of heterozygosity at 6q has a negative impact on prognosis.
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Anaplastic large-cell lymphoma: In contrast to the 3rd edition, the 4th edition (like the WHO book on hematological malignancies 10 ) emphasizes the difference between anaplastic lymphoma kinase (ALK)(+) and ALK(−) anaplastic largecell lymphoma (ALCL). Both arise only exceptionally in the mediastinum. By immunohistochemistry, ALCL must be distinguished from other CD30-positive lymphomas and epithelial membrane antigen-positive solid tumors, including carcinomas, and from melanomas. However, the diagnosis of ALK(−) ALCL versus CD30-positive peripheral T cell lymphoma, NOS, still rests on the identification of "hallmark cells" in a background of large-cell lymphoma, but the distinction may sometimes be arbitrary.
Hodgkin lymphoma:
The diagnostic criteria of HL [virtually all mediastinal cases are nodular sclerosis classical HL (cHL)] have remained unchanged. A number of inactivating mutations, amplifications, and translocations have been described that affect nuclear factor kappa-light-chain-enhancer of activated B cells, Janus kinase and signal transucer and activator of transcription, DNA damage, and apoptosis pathways as well as epigenetic homeostasis (reviewed by Kuppers 71 ). Recognition that genetic and transcriptomic variation of the tumor cells and tumor-associated T cells and macrophages have prognostic relevance is also new. [72] [73] [74] Nonetheless, stage remains the single most important prognostic factor in mediastinal HL.
B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical HL:
In the 3rd edition, this aggressive lymphoma was included in the "grey zone between HL and non-Hodgkin lymphoma." A current synonym is "mediastinal grey zone lymphoma (MGZL)." Refined diagnostic criteria include a sheet-like growth pattern of large, pleomorphic tumor cells including Hodgkin cells, a less prominent inflammatory background than cHL, usually preserved B-cell program (expression of CD20, PAX5, OCT2, BOB.1; clonal immunoglobulin gene rearrangement), expression of CD30 (consistently) and CD15 (variably), and lack of CD10 and ALK1 expressions. There are distinctive genetic and epigenetic features of MGZL in addition to features that overlap with cHL and PMBL (Fig. 6 ).
75-77
Clinical relevance of refined mediastinal lymphoma diagnosis
Accurate diagnosis is essential for the differential treatment of mediastinal cHL, PMBL, and MGZL. Patients with cHL currently receive polychemotherapy that seems to require inclusion of bleomycin and dacarbazin (e.g., ABVD) followed by involved field irradiation for optimal outcome. 78 PMBL, despite its close molecular relationship to cHL, has been treated very differently, e.g., with CHOP and rituximab (R-CHOP) followed by radiotherapy. However, a recent study shows that radiation may be dispensable in PMBL when R-CHOP is replaced by the dose-adjusted etoposide, prednisone, vincristine, cyclophasphamide, doxorubicin plus rituximab regimen (DA-EPOCH-R). 79 This might be advantageous usually in the young female patients with PMBL because mediastinal radiotherapy has potentially serious late effects, such as cardiovascular disease, lung cancer, and breast cancer. 80 For patients with MGZL, DA-EPOCH-R treatment alone may not be sufficient because they more often required additional radiation to achieve long-term complete remission than patients with PMBL. 
Histiocytic and Dendritic Cell Neoplasms of the Mediastinum
Conceptual continuity
The classification of mediastinal histiocytic and dendritic cell tumors was streamlined according to the 4th edition of the WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues.
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Conceptual changes
The only changes are (i) the deletion of the terms "follicular dendritic cell (FDC) tumor" and "interdigitating dendritic cell (IDC) tumor" (i.e., tumors of unknown malignant potential, ICD-O codes: 9758/1 and 9757/1, respectively) because all FDC and IDC neoplasias are now considered malignant; (ii) the addition of the previously neglected "fibroblastic reticular cell tumors," "indeterminate dendritic cell tumors," and rare dendritic cell tumors with mixed phenotypes (hybrid dendritic cell tumors).
Individual changes of histiocytic and dendritic cell tumors:
A new finding is the detection of BRAF mutations in approximately 50% of all cases of Langerhans cell histiocytosis, including mediastinal cases. 81 In terms of differential diagnosis, the new WHO classification of tumors of the thymus clarifies some important diagnostic challenges that need careful immunohistochemical analysis:
1. S100-positive Langerhans cell lesions, indeterminate dendritic cell tumors, and IDC sarcomas must be distinguished from the much more common metastatic melanoma, nerve sheath tumors, and myoepithelial lesions. CD1a+ Langerin+ Langerhans cell neoplasms need to be distinguished from CD1a+ Langerin− indeterminate dendritic cell tumors. 2. The EMA-positive and/or D2-40-positive subset of FDC sarcomas must not be confused with cytokeratin-deficient thymomas, 82 meningioma, and mesothelioma. 3. The cytokeratin-positive, actin-positive, or desminpositive subsets of fibroblastic reticular cell tumors need to be distinguished from spindle cell epithelial tumors (e.g., atypical type A thymomas and sarcomatoid carcinomas), smooth muscle and myofibroblastic tumors, and angiomatoid fibrous histiocytoma.
Myeloid Sarcoma and Extramedullary Leukemia
There have been no conceptual or individual changes.
Soft-Tissue Tumors of the Mediastinum
Conceptual continuity, no conceptual changes The classification of mediastinal soft-tissue tumors was streamlined according to the 4th edition of the WHO Classification of Tumours of Soft Tissue and Bone. 11 There have been no conceptual changes since the 3rd edition of the WHO book (Table 1) .
Individual changes in subtypes of soft-tissue tumors
Diagnostic criteria of all entities are maintained. New, diagnostically useful genetic alterations when compared with the 3rd edition are STAT6 translocation in solitary fibrous tumors 83 and MYC gene amplification in radiation-induced (angio-) sarcomas. 84, 85 In contrast to the WHO Classification of Tumours of Soft Tissue and Bone, 11 the 3rd and 4th editions of the WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart cover neurogenic tumors that are among the most common tumors in the posterior mediastinum. The exceedingly rare neuroblastomas and ganglioneuroblastomas of the thymic region are unusual because they occur in elderly patients. 86, 87 It is unknown, whether they are genetically distinct from their childhood counterparts.
Ectopic Tumors of the Thymus and Metastasis to the Thymus
PERSPECTIVES AND CHALLENGES
The molecular revolution has just begun to approach TETs, 22, 24 but the understanding of their biology is far away from the level reached in many hematological and solid tumors. However, The Cancer Genome Atlas has recently included TETs for analysis of genetic, transcriptomic, and epigenetic changes in relation to clinicopathologic and followup data. Exploiting the databases compiled by the ITMIG [6] [7] [8] [9] might further promote our understanding of TETs and open perspectives for targeted therapies. In addition to this benchto-bedside perspective, new clues to the molecular and cellular pathogenesis of thymic tumors can also be expected through clinical trials 22 that segregate patients into responders and nonresponders and thus open new avenues for bedside-to-bench studies of unknown underlying molecular mechanisms. 29 An intriguing new molecular finding that may give a first hint to the etiology of TETs is the recent description of human polyomavirus 7 in the epithelial cells of the majority of TETs and of some hyperplastic thymuses of adults but not of fetal thymic tissue. 88 If confirmed, this might have an impact on the classification of TETs and their clinical management.
Finally, a new staging system for thymomas and thymic carcinomas is on the horizon 15 but awaits approval by UICC and AJCC.
Taken together, the 4th edition of the WHO Classification of thymic tumors has added important new data to the previous edition but can be expected to require amendments or additions because of significant new discoveries before long.
What are the challenges that need to be tackled in the years ahead to translate a foreseeable better understanding of thymoma and thymic carcinoma biology into improved management of patients? A so far unresolved key problem that has strongly inhibited functional in vitro and preclinical in vivo studies is the paucity of permanent bona fide thymoma and thymic carcinoma cell lines 26, 89, 90 and the virtual absence of relevant spontaneous and xenograft-based animal models. 91 Except for the rarity of thymomas and thymic carcinomas, the lack of cell lines and functional xenografts is likely because of the essential need of neoplastic thymic epithelial cells for crosstalk with stromal cells and particularly developing T cells in the case of thymomas to prevent senescence in vitro. 26 Therefore, systems biology approaches will likely be necessary to decipher the complex ligand-based and paracrine networks that help to sustain the survival of neoplastic epithelial cells in vivo and might be essential in vitro as well. This knowledge might be a prerequisite to
